Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
acetominophen · 1 trial · 1 indication
Pain severity was rated by the participants in a paper diary by grade; Grade 0 (no pain), Grade 1 (mild pain), Grade 2 (moderate pain), and Grade 3 (severe pain). Pain freedom was defined as a reduction in pain severity from moderate to severe migraine headache (Grade 2 or 3) to no pain (Grade 0).
An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.
An adverse event is any unfavorable and unintended change in the structure, function, or chemistry of the body whether or not considered related to the study treatment.
| Arm | Type | Description |
|---|---|---|
| Placebo | PLACEBO_COMPARATOR | Participants take two placebo tablets and two placebo capsules, orally, at onset of migraine |
| Telcagepant 280 mg +Ibuprofen 400 mg | EXPERIMENTAL | Participants take one telcagepant 280 mg tablet, one ibuprofen 400 mg tablet, and two placebo capsules, orally, at onset of migraine |
| Telcagepant 280 mg +APAP 1000 mg | EXPERIMENTAL | Participants take one telcagepant 280 mg tablet, one placebo tablet, and two 500-mg APAP capsules, orally, at onset of migraine |
| Telcagepant 280 mg | PLACEBO_COMPARATOR | Participants take one telcagepant 280 mg tablet, one placebo tablet, and two placebo capsules, orally, at onset of migraine |
| Name | Type | Description |
|---|---|---|
| placebo | DRUG | - |
| ibuprofen | DRUG | - |
| acetominophen | DRUG | - |
| telcagepant | DRUG | - |
Inclusion Criteria: * Must be 18 years of age or older * History of migraine with or without aura for more than 1 year with 1-8 moderate or severe migraine attacks per month in the 2 months prior to starting in the study * Willing to stay awake for at least 2 hours after taking study drug * Able to...
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| AbbVie, Inc. | ABBV | 13 | PHASE3 | Atogepant |
| Pfizer Inc. | PFE | 9 | PHASE3 | Rimegepant |
| Eli Lilly and Company | LLY | 2 | PHASE3 | Galcanezumab |
| Amgen Inc. | AMGN | 2 | PHASE3 | Erenumab Dose 1 |
| Ki Health Partners. LLC | RVNC | 1 | - | Daxibotulinumtonix A |
Acetominophen is a small molecule being studied for the treatment of migraine with or without aura. In clinical research, it has been evaluated as a co-administered therapy alongside other migraine medications to assess its safety and effectiveness in patients experiencing migraines.
Acetominophen is being developed by Merck & Company, Inc., which trades under the ticker symbol MRK. The company is conducting clinical research to evaluate the drug's potential in treating migraine with or without aura.
Acetominophen is in Phase 2 clinical development. It is an investigational drug and has not been approved by regulatory authorities. The Phase 2 trial has been completed, and the drug remains under evaluation for its safety and effectiveness in migraine treatment.
Acetominophen has been studied in one completed Phase 2 clinical trial, identified as NCT00758836. This randomized, double-blind, placebo-controlled study enrolled 683 participants aged 18 years and older to evaluate the safety and effectiveness of acetominophen co-administered with other migraine medications.
Acetominophen is not the same as telcagepant. The clinical trial NCT00758836 evaluated telcagepant (MK-0974) co-administered with either ibuprofen or acetominophen. Acetominophen was used as a co-administered medication in the study, not as the primary investigational drug.